Your browser is no longer supported. Please, upgrade your browser.
Settings
CORV Correvio Pharma Corp. daily Stock Chart
CORV [NASD]
Correvio Pharma Corp.
Index- P/E- EPS (ttm)-0.46 Insider Own0.80% Shs Outstand47.22M Perf Week18.45%
Market Cap93.97M Forward P/E- EPS next Y-0.44 Insider Trans- Shs Float47.22M Perf Month4.74%
Income-17.10M PEG- EPS next Q-0.18 Inst Own76.60% Short Float1.07% Perf Quarter-17.77%
Sales29.40M P/S3.20 EPS this Y29.50% Inst Trans-0.16% Short Ratio3.85 Perf Half Y-38.01%
Book/sh-0.01 P/B- EPS next Y38.90% ROA-54.20% Target Price6.05 Perf Year-57.39%
Cash/sh0.27 P/C7.28 EPS next 5Y28.00% ROE-575.20% 52W Range1.43 - 5.15 Perf YTD-20.08%
Dividend- P/FCF- EPS past 5Y-26.80% ROI-16.30% 52W High-61.36% Beta0.46
Dividend %- Quick Ratio1.50 Sales past 5Y44.80% Gross Margin72.00% 52W Low39.16% ATR0.16
Employees173 Current Ratio1.70 Sales Q/Q19.40% Oper. Margin-84.60% RSI (14)56.99 Volatility11.10% 9.37%
OptionableYes Debt/Eq- EPS Q/Q-267.40% Profit Margin- Rel Volume0.70 Prev Close1.99
ShortableYes LT Debt/Eq- EarningsAug 14 BMO Payout- Avg Volume131.69K Price1.99
Recom2.00 SMA2013.02% SMA500.06% SMA200-27.81% Volume0 Change0.00%
Dec-04-18Initiated B. Riley FBR Buy $7
Oct-12-18Upgrade Mackie Research Hold → Buy
Aug-16-19 02:45PM  Is Correvio Pharma (TSE:CORV) Using Too Much Debt? Simply Wall St.
Aug-14-19 07:00AM  Correvio Reports Second Quarter 2019 Financial Results CNW Group
Aug-12-19 08:00AM  Correvio Announces Brinavess® Spectrum Data to be Presented at the European Society of Cardiology 2019 Congress PR Newswire +6.83%
Aug-08-19 08:00AM  Correvio to Report Second Quarter 2019 Financial Results CNW Group
Aug-07-19 09:20AM  Correvio Closes Public Offering of 9,200,000 Common Shares PR Newswire
Aug-02-19 09:10AM  Correvio Announces Pricing Of Public Offering Of Common Shares PR Newswire -15.14%
Aug-01-19 04:24PM  Correvio Announces Overnight Marketed Offering of Common Shares PR Newswire
Jul-25-19 07:00AM  U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant) PR Newswire
Jun-29-19 06:19PM  Hedge Funds Have Never Been This Bullish On Correvio Pharma Corp. (CORV) Insider Monkey
Jun-24-19 07:00AM  Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation CNW Group
Jun-18-19 07:10PM  Correvio Announces Voting Results CNW Group
May-08-19 08:26AM  Correvio: 1Q Earnings Snapshot Associated Press
08:00AM  Correvio Reports First Quarter 2019 Financial Results PR Newswire
08:00AM  Correvio Reports First Quarter 2019 Financial Results CNW Group
May-01-19 08:00AM  Correvio to Report First Quarter 2019 Financial Results on May 8, 2019 PR Newswire +5.86%
08:00AM  Correvio to Report First Quarter 2019 Financial Results on May 8, 2019 CNW Group
Apr-09-19 09:45AM  Cannabis Industry Consuming Energy at An Alarming Rate: Investing in Solutions ACCESSWIRE
Apr-03-19 09:29AM  Correvio Announces Zevtera® Abstracts at ECCMID 2019 PR Newswire
09:29AM  Correvio Announces Zevtera® Abstracts at ECCMID 2019 CNW Group
09:28AM  Correvio Announces Xydalba (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019 PR Newswire
09:28AM  Correvio Announces Xydalba (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019 CNW Group
Apr-02-19 08:00AM  Correvio to present at the H.C. Wainwright Global Life Sciences Conference CNW Group
Mar-20-19 08:00AM  Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting PR Newswire -5.39%
Mar-14-19 07:00AM  Correvio Announces at the Market Offering PR Newswire
Mar-13-19 07:00AM  Correvio Reports Fourth Quarter and Full Year 2018 Financial Results CNW Group -7.14%
Mar-11-19 08:00AM  Correvio Announces Amendment To Term Loan With CRG-Managed Funds CNW Group +5.79%
Mar-07-19 08:00AM  Correvio to Present at Upcoming Investor Conferences PR Newswire +5.68%
08:00AM  Correvio to Present at Upcoming Investor Conferences CNW Group
Mar-06-19 08:00AM  Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019 PR Newswire
08:00AM  Correvio To Report Fourth Quarter And Full Year 2018 Financial Results On March 13, 2019 CNW Group
Feb-21-19 08:00AM  Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference PR Newswire
Feb-07-19 08:00AM  Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress CNW Group +19.35%
Jan-17-19 08:00AM  Correvio Provides Update On At The Market Offering PR Newswire +25.88%
Jan-02-19 08:00AM  Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes CNW Group
Nov-26-18 10:00AM  CORV: Topline Growth Accelerating Zacks Small Cap Research
Nov-20-18 07:00AM  Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference CNW Group
Nov-06-18 04:00PM  Correvio Reports Third Quarter 2018 Financial Results CNW Group
Oct-31-18 10:00AM  CORV: Brinavess Continues to Hit Milestones Zacks Small Cap Research -6.11%
Oct-30-18 07:00AM  Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018 CNW Group
Oct-29-18 07:00AM  Correvio Announces Brinavess Eligibility for Patent Extension PR Newswire
07:00AM  Correvio Announces Brinavess Eligibility for Patent Extension CNW Group
Oct-23-18 07:00AM  Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019 PR Newswire +25.96%
Oct-01-18 09:15AM  CORV: Brinavess Continues to Lead Zacks Small Cap Research -5.47%
Sep-20-18 04:01PM  Correvio to Participate In Upcoming Investor Conferences PR Newswire
Sep-05-18 07:00AM  Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study PR Newswire +13.77%
Sep-04-18 07:00AM  Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics CNW Group
Aug-31-18 02:44PM  Penny Stocks to Watch for September 2018 Investopedia
Aug-28-18 07:00AM  Correvio to Participate in Upcoming Investor Conferences CNW Group
Aug-16-18 07:00AM  Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients PR Newswire +11.40%
Aug-14-18 04:00PM  Correvio Reports Second Quarter 2018 Financial Results PR Newswire
04:00PM  Correvio Reports Second Quarter 2018 Financial Results CNW Group
02:30PM  Cardiome Pharma Corp. to Host Earnings Call ACCESSWIRE
07:00AM  Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China PR Newswire
Aug-07-18 08:00AM  Correvio To Report Second Quarter 2018 Financial Results On August 14, 2018 CNW Group
Aug-01-18 08:00AM  Correvio to present at the Canaccord Genuity 38th Annual Growth Conference CNW Group
Jul-10-18 08:49AM  Correvio Announces At The Market Offering CNW Group
Jun-29-18 09:00AM  Penny Stocks to Buy Using Technical Analysis Investopedia
Jun-14-18 04:13PM  What You Must Know About Correvio Pharma Corps (TSE:CORV) Financial Strength Simply Wall St.
Jun-12-18 08:10AM  Todays Research Reports on Stocks to Watch: CRISPR Therapeutics and Cardiome Pharma ACCESSWIRE +16.33%
Jun-11-18 08:00AM  Correvio Provides U.S. Regulatory Update for BRINAVESS PR Newswire +44.23%
Jun-06-18 08:00AM  Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS CNW Group
May-31-18 05:46PM  Where Correvio Pharma Corps (TSE:CORV) Earnings Growth Stands Against Its Industry Simply Wall St.
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.